Expert consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the determination of biomarkers in pancreatic and biliary tract cancer

• Ruth Vera ^[3] ; Carolina Ibarrola-de-Andrés ^[1] ; Jorge Adeva ^[1] ; Judith Pérez-Rojas ^[4] ; Pilar García-Alfonso ^[5] ; Yolanda Rodríguez-Gil ^[1] ; Teresa Macarulla ^[6] ; Teresa Serrano-Piñol ^[7] ; Rebeca Mondéjar ^[8] ; Beatriz Madrigal-Rubiales ^[2]
  1. [1] Hospital Universitario 12 de Octubre

     Hospital Universitario 12 de Octubre

     Madrid, España

     
  2. [2] Hospital Universitario Pío del Río Hortega

     Hospital Universitario Pío del Río Hortega

     Valladolid, España

     
  3. [3] Hospital Universitario de Navarra, Sociedad Española de Oncología Médica (SEOM), Calle Irunlarrea, 3, Navarra, 31008, Pamplona, España
  4. [4] Hospital Universitari i Politècnic La Fe, Sociedad Española de Patología (SEAP), Valencia, España
  5. [5] Hospital Universitario Gregorio Marañón, Sociedad Española de Oncología Médica (SEOM), Madrid, España
  6. [6] Hospital Universitario Vall d’Hebron, Sociedad Española de Oncología Médica (SEOM), Barcelona, España
  7. [7] Hospital Universitario Bellvitge, Sociedad Española de Patología (SEAP), Barcelona, España
  8. [8] Hospital Universitario La Princesa, Sociedad Española de Oncología Médica (SEOM), Madrid, España

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 24, Nº. 11 (November), 2022, págs. 2107-2119
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Pancreatic cancer and biliary tract cancer have a poor prognosis. In recent years, the development of new diagnostic techniques has enabled the identification of the main genetic alterations involved in the development of these tumours. Multiple studies have assessed the ability of certain biomarkers, such as BRCA in pancreatic cancer, IDH1 or FGFR2 in biliary tract cancer and microsatellite instability or NTRK fusions in an agnostic tumour fashion, to predict response to treatment.

    In this consensus, a group of experts selected by the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP) reviewed the role played by these mutations in the process of carcinogenesis and their clinical implications. As a result, this article proposes a series of recommendations to optimize the determination of these biomarkers to help standardize the diagnosis and treatment of these tumours.